Proportion of Community-Dwelling Individuals Older Than 70 Years Eligible for Lecanemab Initiation: The Gothenburg H70 Birth Cohort Study.

Anna Dittrich Erik WestmanSara ShamsTobias SkillbäckHenrik Zetterberg Kaj BlennowAnna ZettergrenIngmar SkoogSilke Kern

Published in: Neurology (2024)

Information on proportion of individuals eligible for AD treatment with lecanemab in the general public is limited. We provide information on 70-year-olds in Sweden and extrapolate these data to Europe and the United States. This study opens for larger studies on this proportion and implementation of lecanemab treatment.

Keyphrases

community dwelling
healthcare
mental health
emergency department
machine learning
quality improvement
middle aged
big data
deep learning
social media
replacement therapy
preterm birth
drug induced